List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for the given year is not complete until April of the following year. Annual Reports data is a snapshot of agency reported information for that year and hence might look different from the live data in the Awards Information charts.

  1. Therapeutic D-peptide Inhibitor of HIV Entry

    SBC: NAVIGEN, INC.            Topic: NIAID

    DESCRIPTION provided by applicant With million people living with HIV AIDS including million in the US and million AIDS related deaths annually HIV AIDS remains a formidable global epidemic UNAIDS CDC Modern HIV therapy combines drugs from different classes to form andquot cocktailandquot therapies that have significantly prolonged the lives of many HIV patients However side effects and drug resis ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis

    SBC: GLYCOMIRA, LLC            Topic: NIDCR

    DESCRIPTION provided by applicant Chronic gingival inflammation of the soft tissue surrounding the tooth afflicts over half of all American adults In the most severely affected progression of this inflammatory process to the deeper periodontal ligaments and alveolar bone results in tooth loss from loss of mandibular anchorage Gingivitis and periodontitis are initiated by chronic infection o ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Non-Invasive Treatment for Uveitis

    SBC: ACIONT, INC.            Topic: N

    DESCRIPTION provided by applicant The aim of this innovative proposal is to commercialize a non invasive topical product that treats uveitis which is safe and easy to administer Uveitis is the third leading cause of blindness in the United States Heretofore the primary treatment of intermediate and posterior uveitis has been either oral medications with significant systemic side effects or ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian Cancer

    SBC: TheraTarget, Inc.            Topic: NCI

    DESCRIPTION provided by applicant The purpose of this Phase II STTR project is to develop a polymeric system for the combination delivery of two antineoplastic agents gemcitabine and paclitaxel Based on the successful results of the STTR Phase I award this Phase II proposal details the rationale and research plan for the synthesis and evaluation of in vivo efficacy of two novel macromolecula ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Cost-effective MHz rate Optical Coherence Tomography for biomedical applications

    SBC: WASATCH PHOTONICS, INC.            Topic: NIBIB

    DESCRIPTION provided by applicant During this SBIR Phase I project we propose to build and test in phantoms a prototype of an innovative cost effective Optical Coherence Tomography OCT system with a X increase in acquisition rate compared to commercially available systems Further development may add an additional X increased acquisition rate for a total of X Current market demand for ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Blocking a novel cytokine signaling pathway for the treatment of rheumatoid arthr

    SBC: NAVIGEN, INC.            Topic: NIAMS

    DESCRIPTION provided by applicant In spite of remarkable progress in management of rheumatoid arthritis RA a devastating autoimmune disease that affects million Americans causing chronic inflammation of joints and surrounding tissues the gap of unmet needs in this therapeutic field remains wide open First of all almost of the patients do not respond adequately to the most advanced ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Rapid Monitoring and Assessment of Tubercuolosis Treatment at the Point of Care Using Breath

    SBC: NanoSynth Materials and Sensors Inc.            Topic: NHLBI

    DESCRIPTION provided by applicant Problem and Significance According to the CDC global statistics nearly of the world is infected with Tuberculosis TB In million f peopled infected lived in what is considered a high burden country Countries such as India Peru China sub Saharan Africa and others have significant regions endemic for TB particularly among the lower income ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Arf6 inhibitors for the treatment of uveal melanoma

    SBC: NAVIGEN, INC.            Topic: 102

    DESCRIPTION provided by applicant Activating mutations in G proteins are the drivers of oncogenesis in numerous cancers Therefore identifying drugs that block the signaling pathways controlled by these mutations could have enormous therapeutic consequences Uveal melanoma is a prototypical G driven cancer in which about of tumors have activating mutations in one of two G encoding genes ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Targeted Intraceptor Nanoparticle for Macular Degeneration

    SBC: IVEENA DELIVERY SYSTEMS, LLC            Topic: N

    DESCRIPTION provided by applicant Age related macular degeneration AMD is a leading cause of blindness in United States and many other industrialized nations There are two types of AMD the andquot dryandquot and andquot wetandquot forms Dry AMD is a chronic disease that usually causes variable degree of visual impairment In contrast in wet AMD which affects of AMD patients t ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Treating Acute Lung Injury via Cytokine Signaling Blockade

    SBC: NAVIGEN, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant Acute lung injury ALI and acute respiratory distress syndrome ARDS result from a common pathogenic process pulmonary injury or infection triggers an overwhelming inflammatory response andquot cytokine stormandquot that results in increased endothelial and epithelial permeability and efflux of inflammatory cells protein and water from the vascular syst ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government